Eikon Therapeutics EIKN 深 沪
已收盘 08-14 16:00:00 美东时间
11.05
+0.720
+6.97%
华盛通- 最 高11.30
- 今 开10.72
- 成交量 63.77万股
- 最 低 9.70
- 昨 收 10.33
- 总市值 5.98亿
- 52周最高 17.40
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 7.90
- 委 比 44.14%
- 总股本 5413.86万
- 历史最高 17.40
- 量 比 1.32
- 振 幅 15.49%
- 历史最低 7.90
- 每 手 1
- 风险率 2.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eikon Therapeutics, Inc. GAAP EPS of -$1.63 misses by $0.03
Eikon Therapeutics, Inc. press release (EIKN): Q2 GAAP EPS of -$1.63 misses by $0.03. As of June 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $531.2 million. Eikon expects ...
08-14 04:59
Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial
Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespecified analysis DMC recommended that the TeLuRide-006 study continue as p...
08-11 19:32
Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.
Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.
07-27 22:19
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Eupraxia Pharmaceuticals Inc. announced updates to its executive leadership and operational structure to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, bringing 25 years of experience in technical operations, CMC, and regulatory strategy. Dr. Alex Therien was appointed Executive Vice President, Research & Development, with over 20 years of biopharmaceut...
07-13 20:05
Eikon Therapeutics Set To Join Russell 3000 Index, Effective June
Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, ef...
06-26 04:15
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
05-13 01:24
Eikon Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Eikon Therapeutics shares are trading higher after the company reported better-...
05-12 21:15
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.
05-12 20:39
Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate
Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analyst consensus estimate of $(4.07) by 39.56 percent. This is a 90.86 percent increase over losses of $(26.91) per share
05-12 04:19
